1.Jorge, RE, Robinson, RG, Starkstein, SE, Arndt, SV, Forrester, AW, Geisler, FH. Secondary mania following traumatic brain injury. Am J Psychiatry. 1993;150:916–921.
2.van Reekum, R, Cohen, T, Wong, J. Can traumatic brain injury cause psychiatric disorders? J Neuropsychiatry Clin Neurosci. 2000;12:316–327.
3.Jorge, R, Robinson, RG. Mood disorders following traumatic brain injury. Int Rev Psychiatry. 2003;15:317–327.
4.Warden, DL, Gordon, B, McAllister, TW, et al.Guidelines for the pharmacologic treatment of neurobehavioral sequelae of traumatic brain injury. J Neurotrauma. 2006;23:1468–1501.
5.Starkstein, SE, Pearlson, GD, Boston, J, Robinson, RG. Mania after brain injury. A controlled study of causative factors. Arch Neurol. 1987;44:1069–1073.
6.Stewart, JT, Hemsath, RH. Bipolar illness following traumatic brain injury: treatment with lithium and carbamazepine. J Clin Psychiatry. 1988;49:74–75.
7.Bouvy, PF, van de Wetering, BJ, Meerwaldt, JD, Bruijn, JB. A case of organic brain syndrome following head injury sucessfully treated with carbamazepine. Acta Psychiatr Scand. 1988;77:361–363.
8.Kim, E, Humaran, TJ. Divalproex in the management of neuropsychiatric complications of remote acquired brain injury. J Neuropsychiatry Clip Neurosci. 2002;14:202–205.
9.Pope, HG, McElroy, SL, Satlin, A, Hudson, JI, Keck, PE Jr, Kalish, R. Head injury, bipolar disorder and response to valproate. Compr Psychiatry. 1988;29:34–38.
10.Monji, A, Yoshida, I, Koga, H, Tashiro, K, Tashiro, N. Brain injury-induced rapid-cycling affective disorder successfully treated with valproate. Psychosomatics. 1999;40:448–449.
11.Yassa, R, Cvejic, J. Valproate in the treatment of posttraumatic bipolar disorder in a psychogeriatric patient. J Geriatr Psychiatry Neurol. 1994;7:55–57.
12.Mustafa, B, Evrim, O, Sari, A. Secondary mania following traumatic brain injury. J Neuropsychiatry Clin Neurosci. 2005;17:122–124.
13.Murai, T, Fujimoto, S. Rapid cycling bipolar disorder after left temporal polar damage. Brain Inj. 2003;17:355–358.
14.Arciniegas, DB, Topkoff, J, Silver, JM. Neuropsychiatric aspects of traumatic brain injury. Curr Treat Options Neurol. 2000;2:169–186.
15.Arciniegas, DB, Harris, SN, Brousseau, KM. Psychosis following traumatic brain injury. Int Rev Psychiatry. 2003;15:328–340.
16.Smith, KR Jr. Goulding, PM, Wilderman, D, Goldfader, PR, Holterman-Hommes, P, Wei, F. Neurobehavioral effects of phenytoin and carbamazepine in patients recovering from brain trauma: a comparative study. Arch Neurol. 1994;51:653–660.
17.Hornstein, A, Seliger, G. Cognitive side effects of lithium in closed head injury. J Neuropsychiatry Clin Neurosci. 1989;1:446–447.
18.Massagli, TL. Neurobehavioral effects of phenytoin, carbamazepine, and valproic acid: implications for use in traumatic brain injury. Arch Phys Med Rehabil. 1991;72:219–226.
19.Glenn, MB, Wroblewski, B, Parziale, J, Levine, L, Whyte, J, Rosenthal, M. Lithium carbonate for aggressive behavior or affective instability in ten brain-injured patients. Am J Phys Med Rehabil. 1989;68:221–226.
20.Dikmen, SS, Machamer, JE, Winn, HR, Anderson, GD, Temkin, NR. Neuropsychological effects of valproate in traumatic brain injury: a randomized trial. Neurology. 2000;54:895–902.
21.Temkin, NR, Dikmen, SS, Anderson, GD, et al.Valproate therapy for prevention of posttraumatic seizures: a randomized trial. J Neurosurg. 1999;91:593–600.
22.Wilson, MS, Gibson, CJ, Hamm, RJ. Haloperidol, but not olanzapine, impairs cognitive performance after traumatic brain injury in rats. Am J Phys Med Rehabil. 2003;82:871–879.
23.Rao, N, Jellinek, HM, Woolston, DC. Agitation in closed head injury: haloperidol effects on rehabilitation outcome. Arch Phys Med Rehabil. 1985;66:30–34.
24.Elovic, EP, Lansang, R, Li, Y, Ricker, JH. The use of atypical antipsychotics in traumatic brain injury. J Head Trauma Rehabil. 2003;18:177–195.
25.Stanislav, SW. Cognitive effects of antipsychotic agents in persons with traumatic brain injury. Brain Inj. 1997;11:335–341.
26.Kline, AE, Massucci, JL, Zafonte, RD, Dixon, CE, Defeo, JR, Rogers, EH. Differential effects of single versus multiple administrations of haloperidol and risperidone on functional outcome after experimental brain trauma. Crit Care Med. 2007;35:919–924.
27.Bleiberg, J, Garmoe, W, Cederquist, J. Dexedrine on performance consistency following brain injury: a double-blind placebo crossover case study. Neuropsychiatry Neuropsych Behav Neurol. 1993;6:245–248.
28.Perlis, RH, Welge, JA, Vornik, LA, Hirsctifeld, RM, Keck, PE Jr. Atypical antipsychotics in the treatment of mania: a meta-analysis of randomized, placebo-controlled trials. J Clin Psychiatry. 2006;67:509–516.
29.Krieger, D, Hansen, K, McDermott, C, et al.Loxapine versus olanzapine in the treatment of delirium following traumatic brain injury. NeuroRehabilitation. 2003;18:205–208.
30.Temple, MJ. Use of atypical anti-psychotics in the management of post-traumatic confusional states in traumatic brain injury. J R Army Med Corps. 2003;149:54–55.
31.Bennouna, M, Greene, VB, Defranoux, L. Adjuvant galantamine to risperidone improves negative and cognitive symptoms in a patient presenting with schizophrenialike psychosis after traumatic brain injury. J Clin Psychopharmacol. 2005;25:505–507.
32.Schreiber, S, Klag, E, Gross, Y, Segman, RH, Pick, CG. Beneficial effect of risperidone on sleep disturbance and psychosis following traumatic brain injury. Int Clin Psychopharmacol. 1998;13:273–275.
33.Kim, E, Bijlani, M. A pilot study of quetiapine treatment of aggression due to traumatic brain injury. J Neuropsychiatry Clin Neurosci. 2006;18:547–549.
34.Michals, ML, Crismon, ML, Roberts, S, Childs, A. Clozapine response and adverse effects in nine brain-injured patients. J Clin Psychopharmacol. 1993;13:198–203.
35.Cole, P, Rabasseda, X. Quetiapine in bipolar disorder: increasing evidence of efficacy and tolerability. Drugs Today (Barc). 2004;40:837–852.
36.Serretti, A, De, RD, Lorenzi, C, Berardi, D. New antipsychotics and schizophrenia: a review on efficacy and side effects. Curr Med Chem. 2004;11:343–358.
37.Tandon, R, Jibson, MD. Extrapyramidal side effects of antipsychotic treatment: scope of problem and impact on outcome. Ann Clin Psychiatry. 2002;14:123–129.
38.Bilder, RM, Goldman, RS, Volavka, J, et al.Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorder. Am J Psychiatry. 2002;159:1018–1028.
39.Harvey, PD. Cognitive and functional effects of atypical antipsychotic medications. J Clin Psychiatry. 2006;67:e13.
40.Harvey, PD, Bowie, CR, Loebel, A. Neuropsychological normalization with long-term atypical antipsychotic treatment: results of a six-month randomized, double-blind comparison of ziprasidone vs. olanzapine. J Neuropsychiatry Clin Neurosci. 2006;18:54–63.
41.Macqueen, G, Young, T. Cognitive effects of atypical antipsychotics: focus on bipolar spectrum disorders. Bipolar Disord. 2003;5:53–61.
42.Folstein, MF, Folstein, SE, McHugh, PR. “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12:189–198.
43.Dubois, B, Slachevsky, A, Litvan, I, Pillon, B. The FAB: a Frontal Assessment Battery at bedside. Neurology. 2000;55:1621–1626.
44.Guide for the Uniform Data Set for Medical Rehabilitation (Including the FIMTM instrument), Version 5.1. Buffalo, NY: State University of New York at Buffalo; 1997.
45.Shukla, S, Cook, BL, Mukherjee, S, Godwin, C, Miller, MG. Mania following head trauma. Am J Psychiatry. 1987;144:93–96.
46.Starkstein, SE, Boston, JD, Robinson, RG. Mechanisms of mania after brain injury. 12 case reports and review of the literature. J Nerv Ment Dis. 1988;176:87–100.
47.Starkstein, SE, Mayberg, HS, Berthier, ML, et al.Mania after brain injury: neuroradiological and metabolic findings. Ann Neurol. 1990;27:652–659.
48.Vieta, E, Goikolea, JM. Atypical antipsychotics: newer options for mania and maintenance therapy. Bipolar Disord. 2005;7(suppl):21–33.
49.Newman-Tancredi, A, Gavaudan, S, Conte, C, et al.Agonist and antagonist actions of antipsychotic agents at 5-HT1A receptors: a [35S]GTPgammaS binding study. Eur J Pharmacol. 1998;355:245–256.
50.Bymaster, FP, Falcone, JF, Bauzon, D, et al.Potent antagonism of 5-HT(3) and 5-HT(6) receptors by olanzapine. Eur J Pharmacol. 2001;430:341–349.
51.Tyson, PJ, Roberts, KH, Mortimer, AM. Are the cognitive effects of atypical antipsychotics influenced by their affinity to 5HT-2A receptors? Int J Neurosci. 2004;114:593–611.
52.Yatham, LN, Goldstein, JM, Vieta, E, et al.Atypical antipsychotics in bipolar depression: potential mechanisms of action. J Clin Psychiatry. 2005;66(suppl):40–48.
53.Buhot, MC, Martin, S, Segu, L. Role of serotonin in memory impairment. Ann Med. 2000;32:210–221.
54.Ichikawa, J, Li, Z, Dai, J, Meltzer, HY. Atypical antipsychotic drugs, quetiapine, iloperidone, and melperone, preferentially increase dopamine and acetylcholine release in rat medial prefrontal cortex: role of 5-HT1A receptor agonism. Brain Res. 2002;956:349–357.
55.Velligan, DI, Prihoda, TJ, Sui, D, Ritch, JL, Maples, N, Miller, AL. The effectiveness of quetiapine versus conventional antipsychotics in improving cognitive and functional outcomes in standard treatment settings. J Clin Psychiatry. 2003;64:524–531.
56.Randolph, C. RBANS Manual: Repeatable Battery for the Assessment of Neuropsychological Status. San Antonio, Tex: The Psychological Corporation (Harcourt); 1998.
57.Weickert, TW, Goldberg, TE, Marenco, S, Bigelow, LB, Egan, MF, Weinberger, DR. Comparison of cognitive performances during a placebo period and an atypical antipsychotic treatment period in schizophrenia: critical examination of confounds. Neuropsychopharmacology. 2003;28:1491–1500.
58.Yumru, M, Savas, HA, Kurt, E, et al.Atypical antipsychotics related metabolic syndrome in bipolar patients. J Affect Disord. 2006;98:247–252.
59.Schneider, LS, Dagerman, KS, Insel, P. Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. JAMA. 2005;294:1934–1943.